# Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection

> **NCT05218070** · PHASE1 · UNKNOWN · sponsor: **Eva Pharma** · enrollment: 45 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** EgyVax Vaccine Candidate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05218070
- **Lead sponsor:** Eva Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-06
- **Primary completion:** 2022-10
- **Final completion:** 2023-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218070, "Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05218070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*